Levin V A, Wara W M, Davis R L, Vestnys P, Resser K J, Yatsko K, Nutik S, Gutin P H, Wilson C B
J Neurosurg. 1985 Aug;63(2):218-23. doi: 10.3171/jns.1985.63.2.0218.
The authors report the results of a randomized study conducted to evaluate the relative benefit of treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or the combination of procarbazine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and vincristine (PCV) administered after radiation therapy with hydroxyurea to 76 evaluable patients with glioblastoma multiforme and 72 patients with other anaplastic gliomas. The primary end-point of the study was time to tumor progression. For better-risk patients with Karnofsky performance scores of 70 to 100, results suggest that PCV was of greater benefit than BCNU (p = 0.15 for glioblastoma multiforme; p = 0.13 for other anaplastic gliomas). Median times to tumor progression were 31 and 32 weeks for patients with glioblastoma multiforme; 25th percentile times to progression were 70 and 40 weeks for patients treated with PCV and BCNU, respectively. For patients with other anaplastic gliomas treated with PCV and BCNU, median times to progression were 123 and 77 weeks, respectively. Multivariate analysis showed that the prognostic variables of age and Karnofsky scores were important for patients with glioblastoma multiforme and other anaplastic gliomas, and that the extent of surgical resection was important for those with other anaplastic gliomas.
作者报告了一项随机研究的结果，该研究旨在评估在对76例可评估的多形性胶质母细胞瘤患者和72例其他间变性胶质瘤患者进行羟基脲放疗后，使用1,3-双（2-氯乙基）-1-亚硝基脲（卡莫司汀，BCNU）或丙卡巴肼、1-（2-氯乙基）-3-环己基-1-亚硝基脲和长春新碱（PCV）联合治疗的相对益处。该研究的主要终点是肿瘤进展时间。对于卡诺夫斯基表现评分70至100的较好风险患者，结果表明PCV比BCNU更有益（多形性胶质母细胞瘤患者中p = 0.15；其他间变性胶质瘤患者中p = 0.13）。多形性胶质母细胞瘤患者的肿瘤进展中位时间分别为31周和32周；接受PCV和BCNU治疗的患者的第25百分位数进展时间分别为70周和40周。对于接受PCV和BCNU治疗的其他间变性胶质瘤患者，进展中位时间分别为123周和77周。多变量分析表明，年龄和卡诺夫斯基评分的预后变量对多形性胶质母细胞瘤患者和其他间变性胶质瘤患者很重要，而手术切除范围对其他间变性胶质瘤患者很重要。
